A Phase I Open Label, Multicenter, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Orally Administered CUDC-101 in Subjects With Advanced and Refractory Solid Tumors

Trial Profile

A Phase I Open Label, Multicenter, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Orally Administered CUDC-101 in Subjects With Advanced and Refractory Solid Tumors

Discontinued
Phase of Trial: Phase I

Latest Information Update: 16 Jul 2014

At a glance

  • Drugs CUDC 101 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Biomarker; Pharmacokinetics
  • Sponsors Curis
  • Most Recent Events

    • 05 Jun 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 28 Nov 2012 Curis has determined that the bioavailability of CUDC 101 observed in the first cohort of patients from this trial were too low to warrant the enrollment of additional patients in the current study.
    • 28 Nov 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top